Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Grand Pharmaceutical Group Limited ( (HK:0512) ) just unveiled an announcement.
Grand Pharmaceutical Group has secured approval from China’s National Medical Products Administration to begin a randomized, double-blind, placebo-controlled Phase II clinical trial of GPN01020, its Class 1.1 innovative traditional Chinese medicine for the preventive treatment of migraines. The trial will enroll 180 migraine patients to evaluate efficacy, safety and tolerability, building on over 20 years of clinical use in a Grade A tertiary hospital, where preliminary data indicated that the drug can reduce migraine attack days and frequency and improve related symptoms.
The authorization marks a key milestone in the group’s push to strengthen its Chinese patent medicine portfolio within its ENT segment and deepen its presence in neurology, targeting a major unmet need in migraine prevention amid large disease burden and poor tolerance of some existing therapies. By advancing GPN01020 and other competitive TCM products such as Maixuekang, Danzhen Headache Capsules and Lishukang Capsules, the company is accelerating its shift toward comprehensive chronic disease treatment, enhancing its strategic positioning in China’s pharmaceutical market and supporting its broader dual-cycle, domestic-and-global growth strategy.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a China-focused pharmaceutical company specializing in research, development, production and sales of ENT-related drugs and broader chronic disease treatments. Its portfolio spans ophthalmology, otolaryngology and stomatology, covering chemical and traditional Chinese medicine preparations, prescription and OTC drugs, medical devices and consumer health products, supported by a nationwide marketing network. The group has been strategically expanding its Chinese patent medicine business from a narrow ENT focus into comprehensive chronic disease management, including cerebrocardiovascular and neurological indications, using a carrier-cluster pipeline model to drive new growth areas in cardiology and neurology.
Average Trading Volume: 5,210,911
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.21B
For an in-depth examination of 0512 stock, go to TipRanks’ Overview page.